Net Profit Margins
Bioxcel Therapeutics’s revenue jumped +Inf% since last year same period to $0.01Mn in the Q1 2021. On a quarterly growth basis, Bioxcel Therapeutics has generated 58189900% jump in its revenue since last 3-months.
Bioxcel Therapeutics’s net profit fell -76.89% since last year same period to $-26.38Mn in the Q1 2021. On a quarterly growth basis, Bioxcel Therapeutics has generated -25.09% fall in its net profits since last 3-months.
Bioxcel Therapeutics’s net profit margin jumped NaN% since last year same period to -226636.88% in the Q1 2021. On a quarterly growth basis, Bioxcel Therapeutics has generated 100% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter
EPS Estimate Current Year
Bioxcel Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -1.41 - a -4.44% fall from last quarter’s estimates.
Bioxcel Therapeutics’s earning per share (EPS) estimates for the current year stand at -1.41.
Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)
Bioxcel Therapeutics’s earning per share (EPS) fell -55.21% since last year same period to -1.49 in the Q3 2022. This indicates that the Bioxcel Therapeutics has generated -55.21% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bioxcel Therapeutics’s return on assets (ROA) stands at -0.33.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bioxcel Therapeutics’s return on equity (ROE) stands at -0.74.
|Earnings Date||Estimated EPS||Reported EPS||Surprise %|
555 Long Wharf Drive, New Haven, CT, United States, 06511
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*